Chugai To Remain Unscathed By Roche's Internal Restructuring And Cost-cutting Measures
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Roche Group is in the process of reviewing and implementing a group-wide productivity and cost reduction program, but Japanese partner Chugai will not be directly impacted by the initiative, according to Roche's CEO
You may also be interested in...
Roche Launches Avastin In China For Colon And Rectal Cancer Following Counterfeit Drug Incident In Shanghai
SHANGHAI - Roche announced Sept. 26 the formal launch of its anti-VEGF monoclonal antibody Avastin (bevacizumab) in China for the treatment of metastatic colon and rectal cancer. Roche will also be pursuing other cancer indications in China for the drug
Roche/Ipsen's Suspended Taspoglutide Could Become Another Diabetes Casualty
Roche confirms suspension of dosing in Phase III taspoglutide program after reporting safety problems in June. But Roche's pain could be a gain for the competing GLP-1 Bydureon from Lilly/Amylin/Alkermes.
Roche Announces Internal Review Likely To Result In Staff, Program Cuts
Swiss pharma cites U.S. and EU health care spending constraints and regulatory setbacks as reasons for plan.